JMP Securities Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $31

Futu NewsJan 13 08:32 · Ratings

Promising Potential of Denifanstat Drives Buy Rating for Sagimet Biosciences

TipRanksJan 13 08:05 · Ratings

Institutional Investors Have a Lot Riding on Sagimet Biosciences Inc. (NASDAQ:SGMT) With 43% Ownership

Simply Wall StJan 7 18:39

Express News | Sagimet Biosciences Announces Oral Presentation at the 9TH Annual Mash-Tag 2025 Conference

BreakingsJan 6 21:00

Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

GlobeNewswireJan 6 21:00

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

Yahoo FinanceDec 29, 2024 22:44